The genome backgrounds of multiple myeloma (MM) would affect the efficacy of specific treatment. However, the mutational and transcriptional...

Multiple Myeloma (MM) is the most common primary osseous malignancy in adults, and it mainly affects men aged between 50 and 70 years. Although rare...

Abstract Background Over the last decade there has been considerable research into the treatment, management, and quality of life of people living...

Abstract Background Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real world...